Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Nephrotic Syndrome in a Multiple Sclerosis Patient Receiving Long-term Interferon Beta Therapy.
FDA approval announcement for ofatumumab
Interferon Beta-1b may reverse axonal dysfunction in multiple sclerosis.
Acute pancreatitis: possible association of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis.
Interferon β for secondary progressive multiple sclerosis: a systematic review.
Gut Microbiota in Multiple Sclerosis: Possible Influence of Immunomodulators.
Lithium Controls Central Nervous System Autoimmunity through Modulation of IFN-γ Signaling.
Biogen Third Quarter 2015 Revenues Increase 11% to $2.8 Billion; Company Raises 2015 Full Year Guidance
Placebo-controlled trial of oral laquinimod for multiple sclerosis.
The immunopathology of multiple sclerosis: an overview.
Impact of MS during the critical window of brain development.
Serum from interferon-β-1b-treated patients with early multiple sclerosis stabilizes the blood-brain barrier in vitro.
Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration.
Natalizumab Use During the Third Trimester of Pregnancy.
Neuromyelitis Optica Spectrum Disorders With Aquaporin-4 and Myelin-Oligodendrocyte Glycoprotein Antibodies: A Comparative Study.
Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial.
Fingolimod Impedes Schwann Cell-Mediated Myelination: Implications for the Treatment of Immune Neuropathies?Effect of Fingolimod on Schwann Cells.
Drug Safety Labeling Changes
A novel oral nutraceutical formula of omega-3 and omega-6 fatty acids with vitamins (PLP10) in relapsing remitting multiple sclerosis: a randomised, double-blind, placebo-controlled proof-of-concept clinical trial.
Selective inhibition of the mitochondrial permeability transition pore protects against neuro-degeneration in experimental multiple sclerosis.
Santhera and NIH collaborate to evaluate Catena® in primary progressive multiple sclerosis
Impact of cladribine on soluble adhesion molecules in multiple sclerosis.
Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder.
A genetic screen identifies genes essential for development of myelinated axons in zebrafish.
Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes.
Pages
« first
‹ previous
…
67
68
69
70
71
72
73
74
75
…
next ›
last »